Mazyar Shadman, Deputy Chief Medical officer at Fred Hutch, Professor of Department of Medicine, Hematology and Medical Oncology Division at University of Washington, shared a post on LinkedIn:
“Excited to share that global phase-3 randomized CELESTIAL-TNCLL-2 is now being officially introduced, and I’ll be presenting the Trial-in-Progress (TIP) abstract at ASCO26.
This study compares:
Zanubrutinib plus Sonrotoclax (SZ) vs. Acalabrutinib plus Venetoclax (AV) in patients with treatment-naïve CLL.
As we continue to move toward time-limited, all-oral regimens, an important question remains:
What is the optimal fixed-duration combination for CLL?
Looking forward to the discussion and insights from the community.”
More posts featuring Mazyar Shadman.